Literature DB >> 18811040

The role of bone morphogenetic protein-7 (Osteogenic Protein-1) in the treatment of tibial fracture non-unions. An overview of the use in Belgium.

Stefan Desmyter1, Yannick Goubau, Nadia Benahmed, Alain de Wever, René Verdonk.   

Abstract

The evolution of a fracture non-union is complex; treatment strategies are therefore challenging. The use of BMP-7 could be an interesting adjunct. We present an overview of the monitored use of this product in tibial non-unions in Belgium. Our retrospective data covers 53% (62 patients) of the cases in which it was used between 2001 and 2006. Questionnaires were sent to surgeons who had been using BMP-7 (OP-1) in tibial non-unions in Belgium. Of 55 surgeons contacted, 27 who had been treating 62 patients with a non-union of a tibial fracture responded. These fractures were most commonly treated with an external fixator and 50% of them had already received some form of graft material. Non-union was diagnosed after a median of 365 days (range, 123-1212). Treatment with OP-1 resulted in a clinical healing rate of 79.6% and a radiographic healing rate of 84.9%. Union was reported after a median of 230 (32-872) days clinically and 232 (32-739) days radiographically. We documented a large number of cases of use of BMP-7 in tibial non-union in Belgium. The healing rates of around 80% are comparable to other reports on success rates with BMP-7. Many cases presented originally with open fractures, infected wounds or fractures with bone loss. This makes the reported results even more promising. Further studies are needed to analyse the socio-economical value of this relatively expensive treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18811040

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  8 in total

Review 1.  Clinical application of bone morphogenetic proteins for bone healing: a systematic review.

Authors:  Gopal Shankar Krishnakumar; Alice Roffi; Davide Reale; Elizaveta Kon; Giuseppe Filardo
Journal:  Int Orthop       Date:  2017-04-19       Impact factor: 3.075

2.  Open tibial fractures grade IIIC treated successfully with external fixation, negative-pressure wound therapy and recombinant human bone morphogenetic protein 7.

Authors:  Ireneusz Babiak
Journal:  Int Wound J       Date:  2012-11-19       Impact factor: 3.315

Review 3.  Clinical and Research Approaches to Treat Non-union Fracture.

Authors:  Claudia Schlundt; Christian H Bucher; Serafeim Tsitsilonis; Hanna Schell; Georg N Duda; Katharina Schmidt-Bleek
Journal:  Curr Osteoporos Rep       Date:  2018-04       Impact factor: 5.096

4.  Production of a polyclonal antibody against osteogenic protein-1, and its role in the diagnosis of osteoarthritis.

Authors:  Sonam Choden Bhutia; Takhelmayum Amumacha Singh; Mingma Lhamu Sherpa
Journal:  Singapore Med J       Date:  2014-07       Impact factor: 1.858

5.  [Therapy-resistant tibial pseudarthrosis. Treatment success with BMP-7 combined with autologous bone].

Authors:  S Siebenlist; T Kraus; R Burghardt; S Döbele; U Stöckle; A Ganslmeier
Journal:  Unfallchirurg       Date:  2010-01       Impact factor: 1.000

Review 6.  Treatment of articular cartilage lesions of the knee.

Authors:  Mazen Falah; Gabreil Nierenberg; Michael Soudry; Morris Hayden; Gershon Volpin
Journal:  Int Orthop       Date:  2010-02-18       Impact factor: 3.075

7.  Coating Ti6Al4V implants with nanocrystalline diamond functionalized with BMP-7 promotes extracellular matrix mineralization in vitro and faster osseointegration in vivo.

Authors:  Ivana Nemcakova; Andrej Litvinec; Vaclav Mandys; Stepan Potocky; Martin Plencner; Martina Doubkova; Ondrej Nanka; Veronika Olejnickova; Barbora Sankova; Martin Bartos; Egor Ukraintsev; Oleg Babčenko; Lucie Bacakova; Alexander Kromka; Bohuslav Rezek; David Sedmera
Journal:  Sci Rep       Date:  2022-03-28       Impact factor: 4.379

Review 8.  Bone morphogenetic protein-7: Review of signalling and efficacy in fracture healing.

Authors:  Steven Cecchi; Simon J Bennet; Manit Arora
Journal:  J Orthop Translat       Date:  2015-08-28       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.